bioRxivCell BiologyPreprint
SARS-CoV-2 infected cells sprout actin-rich filopodia that facilitate viral invasion
Y. Jiu, Y. Zhang, X. ZhangiD, Z. Li, H. Yang, D. Tang, S. Zhao, Q. Zhang, B. Li, P. Lappalainen, Z. Cui, H. Liu, H. Li, W. Zhao
Abstract
Emerging COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a great threat to human health and economics. Although SARS-CoV-2 entry mechanism has been explored, little is known about how SARS-CoV-2 regulates the host cell remodeling to facilitate virus invasion process. Here we unveil that SARS-CoV-2 boosts and repurposes filopodia for entry to the target cells. Using SARS-CoV-2 virus-like particle (VLP), real-time live-cell imaging and simulation of active gel model, we reveal that VLP-induced Cdc42 activation leads to the formation of filopodia, which reinforce the viral entry to host cells. By single-particle tracking and sparse deconvolution algorithm, we uncover that VLP particles utilize filopodia to reach the entry site in two patterns, surfing and grabbing, which are more efficient and faster than entry via flat plasma membrane regions. Furthermore, the entry process via filopodia is dependent on the actin cytoskeleton and actin-associated proteins fascin, formin, and Arp2/3. Importantly, either inhibition the actin cross-linking protein fascin or the active level of Cdc42 could significantly hinders both the VLP and the authentic SARS-CoV-2 entry. Together, our results highlight that the spatial-temporal regulation of the actin cytoskeleton by SARS-CoV-2 infection makes filopodia as a highway for virus entry, which emerges as an antiviral target. Significance StatementRevealing the mechanism of SARS-CoV-2 invasion is of great significance to explain its high pathogenic and rapid transmission in the world. We discovered a previously unknown route of SARS-CoV-2 entry. SARS-CoV-2 virus-like particles boost cellular filopodia formation by activating Cdc42. Using state-of-art-technology, we spatial-temporally described how virus utilize filopodia to enter the target cell in two modes: surfing and grabbing. Filopodia can directly transport the virus to endocytic hot spots to avoid the virus from disorderly searching on the plasma membrane. Our study complements current knowledge of SARS-CoV-2 that filopodia and its components not only play an important role in virus release and cell-cell transmission, but also in the entry process, and provides several potential therapeutic targets for SARS-CoV-2. HighlightsO_LISARS-CoV-2 VLP infection promotes filopodia formation by activating Cdc42 C_LIO_LISARS-CoV-2 VLP utilizes filopodia to enter target cell via two modes, surfing and grabbing C_LIO_LIFilopodia disruption compromises the invasion of both VLP and authentic SARS-CoV-2 C_LI
- organism: human
- assay: fluorescence / live-cell microscopy
- research focus: host-pathogen & immune response
- approach: experimental assay
- approach: microscopy & imaging analysis
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Reorganization of F-actin nanostructures is required for the late phases of SARS-CoV-2 replication in pulmonary cells.
J. Swain, P. Merida, … D. Muriaux·bioRxiv·Mar 8, 2022
- Alternative cell entry mechanisms for SARS-CoV-2 and multiple animal viruses
R. Ojha, A. Jiang, … G. Balistreri·bioRxiv·Jul 2, 2023
- High-speed 3D single-virus tracking reveals actin-aided viral trafficking of SARS-CoV-2 on the plasma membrane
Yuxin Lin, Xinrui Lu, … Kevin Welsher·bioRxiv·Apr 6, 2026
- Dual inhibition of vacuolar ATPase and TMPRSS2 is required for complete blockade of SARS-CoV-2 entry into cells
- Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Target for COVID-19
D. Bohan, H. Van Ert, … W. Maury·bioRxiv·Jun 15, 2021
- Extracellular vimentin as a target against SARS- CoV-2 host cell invasion
L. Suprewicz, M. Swoger, … A. E. Patteson·bioRxiv·Jan 8, 2021